Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 0.67 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | ASPH | Q12797 | 1/20 | 0.48 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20110890 | 0.88 | EGLN1 (0.72) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL20109770 | 0.83 | EGLN1 (0.70) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL19808919 | 0.80 | EGLN1 (1.00) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL1218880 | 0.78 | EGLN1 (0.67) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL20109774 | 0.76 | EGLN1 (0.69) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL18121914 | 0.75 | EGLN1 (0.69) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL523153 | 0.74 | THRA (0.84) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL523036 | 0.74 | EGLN1 (0.84) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL19808877 | 0.73 | EGLN1 (1.00) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL30503449 | 0.72 | EGLN1 (1.00) | EGLN1BBOX1FTOTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118739-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
| US-20180118739-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118739-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885BBOX1 785/4885FTO 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.